Catalent to Discuss a Scalable Gene Therapy Manufacturing Process and Early Development Considerations for Orphan Drugs at Upcoming Industry Congress
SOMERSET, N.J. – August 18, 2020 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced it will present at the upcoming World Orphan Drug Congress Annual Meeting, which will take place virtually on Aug. 24 – 26, 2020.
On Monday, Aug. 24 at 12:50 p.m. EDT, Thomas VanCott, Ph.D., Global Head of Product Development, Catalent Cell & Gene Therapy, will present “Creating Commercial-Ready and Scalable Solutions for Gene Therapy Development and Manufacturing”. Dr. VanCott will discuss the challenges involved in developing a reliable and scalable manufacturing process for gene therapies, and the importance of early planning to achieve commercial readiness.
The following day at the same time, Cornell Stamoran, Ph.D., Vice President of Corporate Strategy, and founder of the Catalent Applied Drug Delivery Institute, will present “Preparing for Success: Early Development Considerations for Orphan Drug Commercialization”. In his presentation, Dr. Stamoran will discuss how early drug design decisions can impact an orphan drug product’s potential in terms of risk profile, its speed through development and scale-up to commercial manufacturing, and ultimately its usability by patients.
Dr. VanCott joined Catalent through its acquisition of Paragon Gene Therapy in 2019. Prior to Paragon he spent 14 years as the President and CEO of Advanced Bioscience Laboratories Inc. (ABL), and previously held several positions at the Henry M. Jackson Foundation for the Advancement of Military Medicine. Dr. VanCott received a doctorate in physical chemistry from the University of Virginia, and a bachelor’s degree in chemistry from Dickinson College, Carlisle, Pennsylvania.
Dr. Stamoran leads Catalent’s strategic planning, market intelligence and government affairs efforts. He also founded and serves as Co-Chair of the Catalent Applied Drug Delivery Institute (www.drugdeliveryinstitute.com). He has spent more than 30 years engaged in the healthcare industry, including more than 25 years in advanced drug and biologic delivery and outsourcing.
Notes for Editors
ABOUT CATALENT
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 13,500 people, including over 2,400 scientists and technicians, at more than 40 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com